 Abigail Lara
Concepts (133)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Arginine | 3 | 2017 | 235 | 0.630 |
Why?
| | Nitric Oxide | 4 | 2017 | 814 | 0.500 |
Why?
| | Lymphatic Vessels | 1 | 2012 | 54 | 0.390 |
Why?
| | Collagen | 2 | 2012 | 411 | 0.370 |
Why?
| | Arginase | 1 | 2008 | 26 | 0.300 |
Why?
| | Lung Diseases, Interstitial | 2 | 2012 | 494 | 0.300 |
Why?
| | Fibroblasts | 1 | 2012 | 827 | 0.300 |
Why?
| | Hemorrhage | 1 | 2010 | 599 | 0.260 |
Why?
| | Severity of Illness Index | 1 | 2012 | 2530 | 0.240 |
Why?
| | Lung Diseases | 1 | 2010 | 688 | 0.220 |
Why?
| | Pulmonary Fibrosis | 3 | 2011 | 321 | 0.220 |
Why?
| | Pulmonary Artery | 2 | 2007 | 1012 | 0.210 |
Why?
| | Asthma | 3 | 2017 | 2016 | 0.210 |
Why?
| | Bronchoalveolar Lavage | 2 | 2013 | 82 | 0.190 |
Why?
| | Biopsy | 3 | 2013 | 1024 | 0.170 |
Why?
| | Bleomycin | 2 | 2011 | 227 | 0.170 |
Why?
| | Idiopathic Pulmonary Fibrosis | 2 | 2016 | 500 | 0.150 |
Why?
| | Hypertension, Pulmonary | 3 | 2011 | 1733 | 0.130 |
Why?
| | Case-Control Studies | 4 | 2012 | 2993 | 0.130 |
Why?
| | Bronchi | 1 | 2017 | 222 | 0.130 |
Why?
| | Cholestyramine Resin | 1 | 2015 | 7 | 0.130 |
Why?
| | Isoxazoles | 1 | 2015 | 51 | 0.120 |
Why?
| | Prosthesis-Related Infections | 1 | 2015 | 69 | 0.120 |
Why?
| | Mucin-5B | 1 | 2016 | 184 | 0.110 |
Why?
| | Breath Tests | 2 | 2017 | 81 | 0.110 |
Why?
| | Shock, Septic | 1 | 2015 | 185 | 0.110 |
Why?
| | Antirheumatic Agents | 1 | 2015 | 253 | 0.110 |
Why?
| | Anesthesia, General | 1 | 2013 | 44 | 0.100 |
Why?
| | Transforming Growth Factor beta | 2 | 2012 | 435 | 0.100 |
Why?
| | Vascular Endothelial Growth Factor D | 1 | 2012 | 12 | 0.100 |
Why?
| | Silicosis | 1 | 2013 | 22 | 0.100 |
Why?
| | Vascular Endothelial Growth Factor C | 1 | 2012 | 16 | 0.100 |
Why?
| | Lymphangiogenesis | 1 | 2012 | 24 | 0.100 |
Why?
| | Lung Injury | 2 | 2011 | 192 | 0.100 |
Why?
| | Lung | 3 | 2013 | 3497 | 0.090 |
Why?
| | Promoter Regions, Genetic | 1 | 2016 | 1110 | 0.090 |
Why?
| | Myofibroblasts | 1 | 2012 | 115 | 0.090 |
Why?
| | Lactic Acid | 1 | 2012 | 269 | 0.090 |
Why?
| | Gene Expression | 1 | 2016 | 1397 | 0.090 |
Why?
| | Spirometry | 2 | 2008 | 220 | 0.090 |
Why?
| | Plasmapheresis | 1 | 2010 | 21 | 0.090 |
Why?
| | Radiography | 1 | 2012 | 803 | 0.090 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2012 | 496 | 0.080 |
Why?
| | Biological Availability | 1 | 2008 | 119 | 0.070 |
Why?
| | Respiration, Artificial | 2 | 2013 | 536 | 0.070 |
Why?
| | Pulmonary Alveoli | 1 | 2010 | 369 | 0.070 |
Why?
| | Adrenal Cortex Hormones | 1 | 2010 | 488 | 0.070 |
Why?
| | Receptors, Immunologic | 1 | 2007 | 195 | 0.070 |
Why?
| | Humans | 15 | 2017 | 113531 | 0.060 |
Why?
| | Immunosuppressive Agents | 1 | 2010 | 633 | 0.060 |
Why?
| | Male | 10 | 2017 | 55112 | 0.060 |
Why?
| | Female | 11 | 2017 | 59115 | 0.060 |
Why?
| | Cell Differentiation | 1 | 2012 | 1681 | 0.060 |
Why?
| | Lung Transplantation | 1 | 2007 | 241 | 0.060 |
Why?
| | Mitral Valve Insufficiency | 1 | 2005 | 69 | 0.060 |
Why?
| | Cell Proliferation | 1 | 2011 | 2164 | 0.060 |
Why?
| | Myocardial Ischemia | 1 | 2005 | 237 | 0.050 |
Why?
| | T-Lymphocytes | 1 | 2011 | 1725 | 0.050 |
Why?
| | Kidney Calculi | 1 | 2003 | 30 | 0.050 |
Why?
| | Superoxide Dismutase | 1 | 2005 | 302 | 0.050 |
Why?
| | Aged | 4 | 2015 | 18944 | 0.050 |
Why?
| | Sulfonamides | 1 | 2005 | 442 | 0.050 |
Why?
| | Antihypertensive Agents | 1 | 2005 | 427 | 0.050 |
Why?
| | Ventricular Dysfunction, Left | 1 | 2005 | 361 | 0.050 |
Why?
| | Glycolysis | 2 | 2017 | 223 | 0.050 |
Why?
| | Polymerase Chain Reaction | 2 | 2016 | 984 | 0.040 |
Why?
| | Endothelium, Vascular | 1 | 2007 | 829 | 0.040 |
Why?
| | Middle Aged | 5 | 2012 | 26552 | 0.040 |
Why?
| | Adult | 5 | 2017 | 30245 | 0.040 |
Why?
| | Kidney Failure, Chronic | 1 | 2003 | 490 | 0.040 |
Why?
| | Respiratory Insufficiency | 2 | 2013 | 285 | 0.040 |
Why?
| | Kidney Transplantation | 1 | 2003 | 537 | 0.040 |
Why?
| | Exhalation | 1 | 2017 | 34 | 0.040 |
Why?
| | Nitric Oxide Synthase Type II | 1 | 2017 | 156 | 0.030 |
Why?
| | Acute Kidney Injury | 1 | 2003 | 676 | 0.030 |
Why?
| | Renal Replacement Therapy | 1 | 2015 | 69 | 0.030 |
Why?
| | Respiratory Mucosa | 1 | 2017 | 251 | 0.030 |
Why?
| | One-Lung Ventilation | 1 | 2013 | 2 | 0.030 |
Why?
| | Pulmonary Alveolar Proteinosis | 1 | 2013 | 15 | 0.030 |
Why?
| | Mice, Inbred C57BL | 2 | 2011 | 4617 | 0.020 |
Why?
| | Lung Compliance | 1 | 2011 | 46 | 0.020 |
Why?
| | Chemokine CXCL1 | 1 | 2011 | 67 | 0.020 |
Why?
| | Intubation, Intratracheal | 1 | 2013 | 216 | 0.020 |
Why?
| | Trauma Severity Indices | 1 | 2011 | 108 | 0.020 |
Why?
| | Acute Disease | 1 | 2013 | 885 | 0.020 |
Why?
| | Familial Primary Pulmonary Hypertension | 1 | 2011 | 190 | 0.020 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2011 | 783 | 0.020 |
Why?
| | Bronchoalveolar Lavage Fluid | 1 | 2011 | 578 | 0.020 |
Why?
| | Treatment Outcome | 2 | 2015 | 9006 | 0.020 |
Why?
| | Receptor for Advanced Glycation End Products | 1 | 2007 | 29 | 0.020 |
Why?
| | Survival Rate | 1 | 2011 | 1634 | 0.020 |
Why?
| | Survival Analysis | 1 | 2010 | 1203 | 0.020 |
Why?
| | Hypoxia | 1 | 2013 | 919 | 0.020 |
Why?
| | Sex Characteristics | 1 | 2011 | 633 | 0.020 |
Why?
| | Sex Factors | 1 | 2011 | 1705 | 0.020 |
Why?
| | DNA Primers | 1 | 2007 | 496 | 0.020 |
Why?
| | Glutathione Peroxidase | 1 | 2005 | 40 | 0.020 |
Why?
| | Mice | 2 | 2011 | 14679 | 0.020 |
Why?
| | Cicatrix | 1 | 2005 | 50 | 0.010 |
Why?
| | Linear Models | 1 | 2007 | 767 | 0.010 |
Why?
| | Adenosine Triphosphate | 1 | 2007 | 426 | 0.010 |
Why?
| | Mitral Valve | 1 | 2005 | 91 | 0.010 |
Why?
| | Age Factors | 1 | 2011 | 2875 | 0.010 |
Why?
| | Anuria | 1 | 2003 | 4 | 0.010 |
Why?
| | Proteus mirabilis | 1 | 2003 | 3 | 0.010 |
Why?
| | Proteus Infections | 1 | 2003 | 4 | 0.010 |
Why?
| | Forced Expiratory Volume | 1 | 2005 | 468 | 0.010 |
Why?
| | Glutathione | 1 | 2005 | 291 | 0.010 |
Why?
| | Respiratory Function Tests | 1 | 2005 | 517 | 0.010 |
Why?
| | Base Sequence | 1 | 2007 | 2080 | 0.010 |
Why?
| | Airway Obstruction | 1 | 2005 | 158 | 0.010 |
Why?
| | Intensive Care Units | 1 | 2007 | 620 | 0.010 |
Why?
| | Length of Stay | 1 | 2007 | 963 | 0.010 |
Why?
| | Echocardiography | 1 | 2005 | 563 | 0.010 |
Why?
| | Predictive Value of Tests | 1 | 2007 | 1783 | 0.010 |
Why?
| | Oxygen | 1 | 2007 | 827 | 0.010 |
Why?
| | Transplantation, Homologous | 1 | 2003 | 373 | 0.010 |
Why?
| | Pneumonia | 1 | 2007 | 561 | 0.010 |
Why?
| | Energy Metabolism | 1 | 2007 | 717 | 0.010 |
Why?
| | Amino Acids | 1 | 2005 | 443 | 0.010 |
Why?
| | Retrospective Studies | 2 | 2010 | 12504 | 0.010 |
Why?
| | Mitochondria | 1 | 2007 | 735 | 0.010 |
Why?
| | Heart Ventricles | 1 | 2005 | 710 | 0.010 |
Why?
| | Animals | 2 | 2011 | 31162 | 0.010 |
Why?
| | Prognosis | 1 | 2007 | 3318 | 0.010 |
Why?
| | Cells, Cultured | 1 | 2007 | 3802 | 0.010 |
Why?
| | Aged, 80 and over | 1 | 2010 | 6296 | 0.010 |
Why?
| | Coronary Artery Disease | 1 | 2005 | 610 | 0.010 |
Why?
| | Oxidative Stress | 1 | 2005 | 1065 | 0.010 |
Why?
| | Cohort Studies | 1 | 2007 | 4880 | 0.010 |
Why?
| | Biomarkers | 1 | 2007 | 3389 | 0.010 |
Why?
| | Prospective Studies | 1 | 2007 | 6189 | 0.010 |
Why?
| | Magnetic Resonance Imaging | 1 | 2005 | 3013 | 0.010 |
Why?
|
|
Lara's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|